CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Valproic Acid and Levocarnitinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00661453
NCT00661453Phase 2Completed
CompareCT.gov

Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)

University of Utah·interventional·Posted Apr 18, 2008·Updated Jun 15, 2015

In Brief

A Phase 2 clinical trial evaluating Valproic Acid and Levocarnitine for Spinal Muscular Atrophy Type I. Completed, enrolled 40 participants across 8 sites in 3 countries.

Detailed Summary

This is a multi-center trial to test safety and evaluate early treatment intervention with valproic acid and carnitine in moderating SMA symptoms of Type I infants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Muscular Atrophy Type I
CountriesCanada, Germany, United States
CollaboratorsFamilies of Spinal Muscular Atrophy, Leadiant Biosciences, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2008
Enrollment StartApr 1, 2008
Primary CompletionMay 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 18.2 years ago

Interventions

Valproic Acid and Levocarnitinedrug

Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight